局部进展期直肠癌先行根治性手术联合TME后辅助FOLFOX化疗:开放标签多中心II期随机对照试验
本研究为前瞻性、开放标签、多中心II期随机试验,纳入可手术切除的局部进展期直肠癌患者,随机比较术前放化疗后TME及辅助化疗(A组)与先行根治性手术TME后辅助FOLFOX化疗(B组)。主要终点为3年无病生存率,假设B组3年DFS为75%、非劣效界值15%。
要点
- 对于MRI评估无CRM受累及侧方淋巴结转移的II/III期直肠癌,先行TME后辅助FOLFOX可能替代术前放化疗。
- 主要终点为3年DFS,非劣效界值设为15%。
- 若达到非劣效,患者可避免放疗相关毒性、缩短疗程并节省费用。
核心结论
- 本研究旨在评估先行根治性手术联合TME后辅助FOLFOX化疗是否非劣于当前标准治疗(术前放化疗后手术及辅助化疗)。
研究设计与样本
- 前瞻性、开放标签、多中心、II期随机对照试验,纳入可手术切除的局部进展期直肠癌患者。
- 患者随机分为A组(术前放化疗后TME及辅助化疗)或B组(先行根治性手术TME后辅助FOLFOX化疗)。
- 临床II/III期且术前MRI定义无CRM受累及无侧方淋巴结转移。
主要发现
- 原文未报告试验结果,仅报告研究设计与假设。
关键数值与推荐
- 主要终点为3年无病生存率(DFS)。
- 次要终点包括5年DFS、局部复发率、全身复发率、成本效果和总生存期。
- 假设B组3年DFS为75%,非劣效界值为15%。
临床怎么用
- 若研究达到非劣效,对于MRI评估无CRM受累及侧方淋巴结转移的II/III期直肠癌患者,可考虑省略术前放化疗。
- 省略术前放化疗可能避免放疗相关毒性、缩短治疗时间并节省医疗费用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preoperative chemoradiotherapy (PCRT) followed by surgery and adjuvant chemotherapy is the current standard treatment for stage II/III rectal cancer. However, radiotherapy in the pelvic area is commonly associated with complications such as anastomotic leakage, sexual dysfunction, and fecal incontinence. Recently, the MERCURY study showed that preoperative high-resolution magnetic resonance imaging (MRI) helped to selectively avoid PCRT. It remains unclear whether PCRT is necessary in patients who can achieve a negative circumferential resection margin (CRM) with surgery alone and in patients with cT1-2N1 or cT3N0 without CRM involvement and lateral lymph node metastasis. This study aims to evaluate the efficacy of upfront radical surgery with total mesorectal excision (TME) followed by adjuvant chemotherapy with folinic acid (or leucovorin), fluorouracil, and oxaliplatin (FOLFOX) versus the current standard treatment in patients with surgically resectable, locally advanced rectal cancer. METHODS: This study, named TME-FOLFOX, is a prospective, open-label, multicenter, phase II randomized trial. Patients with locally advanced rectal cancer will be randomized to receive PCRT followed by TME and adjuvant chemotherapy (arm A) or upfront radical surgery with TME followed by adjuvant FOLFOX chemotherapy (arm B). Clinical stage II/III rectal cancer without CRM involvement and lateral lymph node metastasis will be defined using preoperative MRI. The primary endpoint is 3-year disease-free survival (DFS). Secondary endpoints include 5-year DFS, local recurrence rate, systemic recurrence rate, cost-effectiveness, and overall survival. We hypothesized that our experimental group (arm B) will have a 3-year DFS of 75% and a non-inferiority margin of 15%. DISCUSSION: Identifying whether patients require PCRT is one of the critical issues in locally advanced rectal cancer. This study aims to elucidate whether PCRT may not be required for all patients with stage II/III rectal cancer, especially for the MRI-based intermediate-risk group (with cT1-2N1 or cT3N0) without CRM involvement and lateral lymph node metastasis. If the findings indicate that our proposed treatment, which omits PCRT, is non-inferior to the standard treatment, then patients may avoid unnecessary radiation-related toxicity, have a shorter treatment duration, and save on medical costs. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02167321. Registered on 19 June 2014.
引用
- Lee JB, Kim HS, Jung I, et al. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. Trials. 2020. PMID: 32264919. doi:10.1186/s13063-020-04266-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。